What is the follow-up treatment for a patient after basal cell carcinoma (BCC) excision from the nose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2025 • View editorial policy

From the Guidelines

Follow-up treatment for basal cell carcinoma (BCC) excision from the nose is crucial due to the high risk of recurrence, with 30% to 50% of patients developing another BCC within 5 years.

Key Factors Influencing Prognosis

  • Tumour site: Lesions on the central face, especially around the eyes, nose, lips, and ears, are at higher risk of recurrence 1
  • Tumour size: Increasing size confers higher risk of recurrence 1
  • Histological subtype: Certain subtypes confer higher risk of recurrence 1 ### Follow-up Recommendations
  • Close follow-up: Patients should be closely followed up, especially during the short-term period after diagnosis of the first lesion, as development of a second BCC is most likely during this time 2
  • Long-term surveillance: Continued long-term surveillance of these patients is essential, as is patient education about the values of sun protection and regular self-examination of the skin 2
  • Regular check-ups: Regular check-ups with a dermatologist are necessary to monitor for any signs of recurrence or new lesions 3, 2

From the Research

Follow-up Treatment for Basal Cell Carcinoma (BCC) Excision from the Nose

  • The follow-up treatment for a patient after BCC excision from the nose involves regular monitoring to detect any recurrence or development of new BCCs 4.
  • According to a study published in 2001, 27% of dermatologists reported that they would not review further after excision of a 'well-defined' BCC from inside a central 'T' area on the face, while 37% reported that they would review on one occasion, and 36% reported that they review more than once 4.
  • A study published in 2024 found that patients with high-risk facial BCC treated with interferon had a complete response rate of 73.3% and a recurrence rate of 12.3% after a mean follow-up of 55 months 5.
  • The European consensus-based interdisciplinary guidelines recommend long-term follow-up for patients with high-risk BCC subtypes, high-risk sites, multiple BCCs, and naevoid basal cell carcinoma syndrome (NBCCS) 6.
  • The treatment modality utilized is dependent on both the tumor type and the patient, and evidence-based research is necessary to choose between therapies 7, 8.

Treatment Options

  • Surgical excision, Mohs surgery, and cryosurgery are the three standard therapies of choice for BCC treatment 7.
  • Other treatment modalities, such as photodynamic therapy, topical imiquimod, and topical 5-fluorouracil, may be considered for low-risk superficial BCC 6, 8.
  • Radiotherapy represents a valid alternative to surgery for BCC on the face, especially in elderly patients 6.
  • Hedgehog inhibitors, vismodegib or sonidegib, should be offered to patients with locally advanced and metastatic BCCs 6.

References

Guideline

guidelines for the management of basal cell carcinoma.

British Journal of Dermatology, 2008

Guideline

basal cell skin cancer, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Guideline

basal cell skin cancer, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Research

Basal cell carcinoma: an evidence-based treatment update.

American journal of clinical dermatology, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.